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Community pharmacy practice is evolving from a prod-
uct-oriented focus to an environment where pharmaceuti-
cal care services are provided in order to meet an overall
therapeutic goal (disease management). Specialized ser-
vices may contribute to positive therapeutic outcomes for
patients served and may improve patients' quality of life.
OBJECTIVE: The purpose of this study was to determine
the effects of specialized pharmaceutical care services for
adult asthmatic patients served in community pharmacy
settings on their health-related quality of life.
METHODS: Adult asthmatic patients received special-
ized pharmaceutical services for one year in 7 community
pharmacies located throughout Texas. All intervention
pharmacies were members of a pharmaceutical care net-
work that provided software, enabling pharmacists to
document interactions with patients. All study patients
were insured by Blue Cross/Blue Shield of Texas, patron-
ized an intervention pharmacy, were confirmed asthmat-
ics (by their physician), and were currently taking asthma
medication(s). Juniper's Asthma Quality of Life Ques-
tionnaire, which includes activity, symptom, emotion,
and exposure domains, was used to evaluate quality of
life changes.
RESULTS: A total of 25 patients completed quality of life
questionnaires over the course of the intervention period
and had pharmacist documentation. Quality of life scores
were compared before and during intervention periods.
When mean baseline overall quality of life scores were
compared to mean ending overall quality of life scores for
intervention patients, a statistically significant improve-
ment was found (t = -2.872; df = 20; p =0.009). Statis-
tically significant improvements were also observed in the
activity (t = -2.795; df = 20; p = 0.011) and symptom
(r = -2.913; df = 20; p = 0.009) domains.
CONCLUSIONS: While improved quality of life was as-
sociated with the pharmaceutical care intervention, fur-
ther research involving more patients is needed to ade-
quately determine the extent of benefits that specialized
pharmaceutical care services could provide.
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Since patient adherence is related to dosage schedules and
the number of medications prescribed, we questioned the
relative adherence to and the economic impact of CoRx-
D&M dispensed as separate agents versus ensured pa-
tient adherence with STF-D/M.
OBJECTIVE: Evaluate the economic implications of
changes in patient adherence.
METHODS: Data were extracted from a Canadian, time-
series database of patient-level pharmacy claims (15.8
million pharmacy claims, totaling C$459.3 milliorr' per
year). From 1/1/93 to 8/31/97, 4,880 CoRx-D&M pa-
tients were identified and 1,001 STF-D/M patients were
identified. Over a 56-month period, consecutive claims
were analyzed to determine relative adherence to each
regimen. The adherence results were entered into a deci-
sion analysis model to project economic outcomes.
RESULTS: Adherence gradually declined in the CoRx-
D&M group to 58% by the fifth diclofenac claim produc-
ing a weighted average adherence rate of 61 %. Therefore,
39% of patients received NSAIDs without misoprostol.
This contrasts with the 100% ensured adherence rate with
STF-D/M. Using standard rates of ulcer complications for
high-risk patients, the economic implications of the decline
in adherence results in an increase in health care costs from
$182.14 per patient per month (PPPM) (assuming 100%
adherence) to $191.45 PPPM (assuming 61% adher-
ence)-an incremental increase of $9.01 PPPM. If patients
receiving co-therapy had been receiving STF-D/M, health-
care costs would be reduced from $191.45 PPPM to
$188.86 PPPM-an incremental savings of $2.59 PPPM.
CONCLUSION: Removing the issue of patient non-
adherence that is seen with co-prescribed medications by
prescribing STF-D/M reduces the risk of NSAID-induced
GI complications and decreases overall health care costs.
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Diabetes mellitus is a major and growing European
health problem at all ages and all countries. Diabetic an-
giopathy leads to chronic foot lesion and has a high risk
